Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

ClinicalTrials.gov ID: NCT02167256

Public ClinicalTrials.gov record NCT02167256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT02167256
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Yale University
Other
Enrollment
159 participants

Conditions and interventions

Interventions

  • AZD0530 100mg daily Drug
  • AZD0530 125mg daily Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
55 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2014
Primary completion
Feb 26, 2018
Completion
Feb 26, 2018
Last update posted
Aug 13, 2019

2014 – 2018

United States locations

U.S. sites
21
U.S. states
17
U.S. cities
20
Facility City State ZIP Site status
Barrow Neurological Institute Phoenix Arizona 85013
Banner Sun Health Research Institute Sun City Arizona 85351
University of California, Los Angeles Los Angeles California 90095
Yale Alzheimer's Disease Research Unit New Haven Connecticut 06510
Georgetown University Washington D.C. District of Columbia 20057
Wien Center for Clinical Research/Mount Sinai Medical Center Miami Beach Florida 33140
University of South Florida - Health Byrd Alzheimer Institute Tampa Florida 33613
Northwestern University Chicago Illinois 60611
Rush University Medical Center Chicago Illinois 60612
Indiana University Indianapolis Indiana 46202
University of Iowa Iowa City Iowa 52242
University of Kentucky Lexington Kentucky 40504
Brigham and Women's Hospital Boston Massachusetts 02115
University of Michigan, Ann Arbor Ann Arbor Michigan 48105-2945
Mount Sinai School of Medicine New York New York 10029
University of Rochester Medical Center Rochester New York 14620
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
Oregon Health & Science University Portland Oregon 97239
University of Pittsburgh, Alzheimer's Disease Research Center Pittsburgh Pennsylvania 15213
Roper St. Francis Hospital Charleston South Carolina 29401
University of Washington Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02167256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 13, 2019 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02167256 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →